Institute of Cellular and Regenerative Medicine

The Institute of Cellular and Regenerative Medicine (ICRM) was a clinical-stage biotechnology company based in Florida that specialized in the development and administration of autologous stem cell therapies. The company focused on treating chronic and debilitating conditions, such as congestive heart failure, COPD, and peripheral artery disease, by utilizing a patient's own bone marrow-derived stem cells. ICRM conducted several Phase 1 and Phase 2 clinical trials to evaluate the safety and efficacy of its cellular treatments. While the company gained significant attention for its regenerative medicine approach, it faced regulatory challenges and is currently considered inactive. Its work was closely associated with the Regenocyte brand and early commercial efforts in adult stem cell medicine.